A review of drug patch testing and implications for HIV clinicians.
about
Abacavir pharmacogenetics--from initial reports to standard of careAbacavir-reactive memory T cells are present in drug naïve individualsTrichloroethylene Hypersensitivity Syndrome Is Potentially Mediated through Its Metabolite Chloral HydrateGenotyping for severe drug hypersensitivity.HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review.Antiviral drug allergy.Pharmacogenetics of drug hypersensitivity.Drug hypersensitivity: pharmacogenetics and clinical syndromes.Hypersensitivity reactions to HIV therapy.Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management.Individualization of antiretroviral therapy.Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access programFollow-up assessment of two cases of trichloroethylene hypersensitivity syndrome: A case reportRecent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.Successful translation of pharmacogenetics into the clinic: the abacavir example.HLA and pharmacogenetics of drug hypersensitivity.Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.Using HLA typing to support patients with cancer.Recent advances in the understanding of severe cutaneous adverse reactions.Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice.A severe hypersensitivity reaction to abacavir following re-challenge.Nevirapine patch testing in Thai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity.A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions.A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
P2860
Q27008841-DA9A0AA1-A3EF-4ACA-B6C2-0CCEC36D1D13Q28543405-AF9F54D2-4469-4D6A-A0DB-087A46F51822Q28547560-D9052C0D-A209-4176-8A75-B7648964A615Q33582530-8DFF0ECB-BBA0-4861-8421-10F85AEC97E1Q33666857-1CB4A3E6-CCA6-4D0C-BEB2-D33CFE7AC47DQ34075812-A9847B71-019F-4200-B8C8-97E21AB20054Q34118186-56F15ECC-B683-4EB2-97CD-C509D1C9640CQ34701492-ECAFEF4E-E881-45E3-934D-11B9D9648911Q34976463-E185DE64-D133-41A6-AF9A-D640B1827DCEQ35094201-C6201B7A-4F75-470E-99EC-CC1E62541A11Q36441423-16314ADF-D139-4715-AA2D-E472BB74013CQ36503619-3EF341BE-128E-4E18-BF95-39CD7FE2DF97Q37106911-242DC523-C153-434D-8B05-3D1B1FDCC950Q37121662-CAB15878-048B-4326-B800-5FE539EB20BCQ37389496-4CA054C5-E42F-4BC9-879D-E3430A4779E4Q37436365-7BAA5864-1434-4A39-9501-94CDD69B1FFDQ38037649-23E18931-1D40-40A0-984A-D50B3CEACACEQ38080040-6A853677-D402-461E-944C-8F418A4E6F33Q38287616-14353AFB-7BF8-4662-A619-498B0EC74A7BQ38931289-FD339A0C-84B5-4463-A817-627A637792BCQ39291741-FA1631BE-FA29-4D80-AC3D-7F3E55E29CFEQ40092386-B86A7D01-69A0-4F22-B345-C42DC0C17A76Q40092748-D1D8E73F-7DA0-45CD-A0F3-529B3BFA42C3Q44949302-06008148-4548-403F-B810-4B5E28E58906Q51297747-0B74BB2B-033E-4EAD-9EA9-0768168B9B63
P2860
A review of drug patch testing and implications for HIV clinicians.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
A review of drug patch testing and implications for HIV clinicians.
@ast
A review of drug patch testing and implications for HIV clinicians.
@en
A review of drug patch testing and implications for HIV clinicians.
@nl
type
label
A review of drug patch testing and implications for HIV clinicians.
@ast
A review of drug patch testing and implications for HIV clinicians.
@en
A review of drug patch testing and implications for HIV clinicians.
@nl
prefLabel
A review of drug patch testing and implications for HIV clinicians.
@ast
A review of drug patch testing and implications for HIV clinicians.
@en
A review of drug patch testing and implications for HIV clinicians.
@nl
P2093
P1433
P1476
A review of drug patch testing and implications for HIV clinicians.
@en
P2093
Brigitte Milpied
Derk P Bruynzeel
Neil H Shear
P304
P356
10.1097/QAD.0B013E3282F7CB60
P407
P577
2008-05-01T00:00:00Z